EGFR ligand as a new therapeutic target for lung injury and pulmonary fibrosis.
Project/Area Number |
18590858
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Respiratory organ internal medicine
|
Research Institution | Kyushu University |
Principal Investigator |
HAMADA Naoki Kyushu University, Kyusyu University Hospital, Clinical Fellow (00423567)
|
Co-Investigator(Kenkyū-buntansha) |
KUWANO Kazuyoshi Jikei University, School of Medicine, Department of Internal Medicine, Professor (40205266)
MAEYAMA Takashige KYUSHU UNIVERSITY, Faculty of Medical Sciences, Assistant Professor (40380456)
|
Project Period (FY) |
2006 – 2007
|
Project Status |
Completed (Fiscal Year 2007)
|
Budget Amount *help |
¥3,780,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥480,000)
Fiscal Year 2007: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2006: ¥1,700,000 (Direct Cost: ¥1,700,000)
|
Keywords | pulmonary fibrosis / lung injury / EGFR / apoptosis / amphiregulin |
Research Abstract |
(1). Expression of an EGFR Wand in idiopathic interstitial pneumonia. Amphiregulin is transmembrane glycoprotein, which is a member of epidermal growth factor receptor ligand family. Amphiregulin levels in serum were significantly increased in patients with interstitial pneumonias, especially, in patients with idiopathic pulmonary fibrosis, compared with those of healthy controls. Amphiregulin level form patients with interstitial pneumonia whose lung function was more severe tended to be higher than those from patients whose lung function was in normal range. (2). Expression of an EGFR ligand in bleomycin-induced pneumopathy in mice. The expression of intrinsic amphirgulin in lung tissues was upregulated at14days after bleomycin instillation. (3). Cell signaling pathway of EGFR ligand in bleomycin induced pneumopathy in mice. Amphiregulin treatment enhances the activation of Akt and Erk in lung epithelial cells. Amphiregulin may play a protective role probably through the activation of survival signals in bleomycin-induced pneumopathy in mice. (4). Effect of amphiregulin, an EGFR ligand, on bleomycin擁nduced pneumopathy in mice. The administration of recombinant amphiregulin improved the survival rate and suppressed the degree of inflammation and fibrosis and the number of TUNEL positive cells in lung tissues. (5). Role of EGFR, ligand in lung injury and pulmonary fibrosis. Amphiregulin plays protective role in acute phase of lung injury and fibrosis by a reduction of apoptosis of lung epithelial cells. A mhiregulin also may stimulate over growth of fibroblast in lung lesion and promote pulmonary fibrosis at chronic phase.
|
Report
(3 results)
Research Products
(19 results)